Rituximab-Induced Long-Term Remission in Childhood-Onset, Uncomplicated, Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome: A Follow-Up Study of a Randomized, Placebo-Controlled Trial (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0943; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Conclusion The result suggests that rituximab enables the continuation of effective treatment beyond 1 year and well tolerated in patients with childhood-onset non-refractory FRNS/SDNS. These findings suggest that rituximab may induce a high rate of sustained long-term remission even after B-cell reconstitution in this patient population."
Clinical • Glomerulonephritis • Nephrology • Renal Disease
|
|
Yuka Kimura; Tomoko Horinouchi; Mayumi Sako; Takashi Omori; Tomoyuki Sakai; Tomohiko Yamamura; Riku Hamada; Seiji Tanaka; Masafumi Oka; Koichi Kamei; Kandai Nozu; Kazumoto Iijima
|